Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY) - PubMed
4 hours ago
- #meta-analysis
- #finerenone
- #chronic kidney disease
- Finerenone, a non-steroidal mineralocorticoid receptor antagonist, was evaluated for efficacy and safety across CKD patients, irrespective of disease cause, glycemia, eGFR, or albuminuria levels.
- Pooled analysis of three trials (FIDELIO-DKD, FIGARO-DKD, FIND-CKD) involving 14,574 participants showed finerenone reduced kidney outcome risk by 24% and cardiovascular outcome risk by 20% compared to placebo.
- Finerenone consistently reduced risks of kidney failure, cardiovascular death, heart failure hospitalization, and all-cause death across diverse patient subgroups.
- Hyperkalaemia incidence was higher with finerenone but rarely led to hospitalization, supporting its broad use as a foundational CKD therapy.